Innovus Pharmaceuticals, Inc.

53 articles with Innovus Pharmaceuticals, Inc.

• Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals

  9/12/2019

  Aytu BioScience, Inc. (NASDAQ: AYTU), and Innovus Pharmaceuticals, Inc. (OTCQB: INNV), a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer health products, today announced that the companies have signed a definitive merger agreemen

• Innovus Pharma Reports Quarterly Revenue for the Second Quarter 2019 of $6.8 million, a 27.7% Increase from Prior Quarter

  8/13/2019

  Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, announced today its reported results for the second quarter ended June 30, 2019.

• Innovus Pharmaceuticals to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 13, 2019

  8/9/2019

  Innovus Pharmaceuticals, Inc. announced that the Company will release its second quarter 2019 financial results and provide a corporate update on Tuesday, August 13, 2019, after the close of the U.S. financial markets.

• Innovus Pharmaceuticals Announces that its Delta Prime Savings Club E-Commerce Marketplace is on Track for Annual Sales of Approximately $3 million in 2019

  7/22/2019

  Annual Sales Tracking to Exceed Previous Year Sales of $2 million

• Innovus Pharmaceuticals Announces Progress in Fulfilling the Regulatory and Manufacturing Steps to Receive Market Authorization for FlutiCare® in Canada

  6/19/2019

  Company Also Updates on Additional Revenue-Generating Activity in that Country

• Innovus Pharmaceuticals Receives Notification to Market and Sell CarvaNum® for Muscle Recovery in the European Union

  6/6/2019

  CarvaNum® is the Company’s Fifth E.U. Notified Product

• Acerus Reaches Mutual Agreement with Innovus Pharma to Terminate Distribution and License Agreement for UriVarx® in Canada

  6/6/2019

  Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF.

• Innovus Pharma Expands its OTC Drug Pipeline with the Addition of OmepraCare™ (a Competitor of Prilosec® OTC)

  6/4/2019

  This New Drug OmepraCare™ is Indicated for the Treatment of Frequent Heartburn and is Expected to add Significant Revenue to the Company

• Innovus Pharma Releases Results from Annual Shareholders Meeting

  5/30/2019

  Innovus Pharmaceuticals, Inc. released the final voting results from the Annual Shareholders Meeting held on May 28, 2019.

• Following Its Recent Approval from Health Canada for the Relief of Neuropathy Pain, Innovus Pharma Announces Receipt of Notification to Commercialize Diabasens® in the European Union

  5/28/2019

  We are pleased to announce the receipt of the CPNP in the European Union for Diabasens®, our current best-selling product.

• Innovus Pharma Reports Quarterly Revenue for the First Quarter 2019 of $5.4 Million, a 18.0% Increase from Comparable Quarter in the Prior Year

  5/15/2019

  nnovus Pharmaceuticals, Inc. announced its reported results for the three months ended March 31, 2019.

• Innovus Pharma’s Partner Lavasta Receives Approval from Algeria to Market and Sell Zestra® and Zestra Glide® in that Country

  5/13/2019

  Innovus Pharmaceuticals, Inc. announced that its partner, Lavasta Pharma RFZ-LLC (“Lavasta”), a company based in Dubai, received approval from the Algerian Ministry of Health and Commerce to market and sell the Company’s Zestra® and Zestra Glide® products in that country.

• Innovus Pharmaceuticals Reports Preliminary Q1 2019 Sales Revenue of Approximately $5.4 million

  5/6/2019

  Preliminary Quarterly Revenue Increase of 12.8% Comparable to 2018 Fourth Quarter and Increase of 18.0% Comparable to 2018 First Quarter

• Innovus Pharma Announces FDA Approval of New ANDA for Supply of FlutiCare®

  4/18/2019

  Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has approved abbreviated new drug application (“ANDA”) No. 208024 for Fluticasone Propionate Nasal Spray USP,

• Innovus Pharma Receives Expanded Claims for Its UriVarx® Product in Canada to Include Symptoms of Urinary Incontinence

  4/4/2019

  Innovus Pharmaceuticals, Inc. announced that its marketed product UriVarx® has received approval for an expanded claim to include “helps improve the symptoms of urinary incontinence.” Innovus Pharma currently sells this product in Canada exclusively through its distributor, Acerus Pharmaceuticals Corporation.

• Innovus Pharma Reports Record Annual Revenue for Fiscal 2018 of $24.0 million in line with Previous Guidance and Product Gross Margins of 81%

  4/1/2019

  Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, announced today its reported results for the fiscal year 2018.

• Innovus Pharmaceuticals to Release its Annual 2018 Financial Results on Monday, April 1, 2019

  3/27/2019

  Innovus Pharmaceuticals, Inc. announced that it will release its annual 2018 calendar year financial results on Monday, April 1, 2019, after the close of the U.S. financial markets.

• Innovus Pharmaceuticals Reports Preliminary Annual 2018 Net Revenue of $24 Million

  3/21/2019

  Preliminary Annual Revenue Increase by 2.7x Compared to Prior Year

• Innovus Pharma Announces the Approval of its RecalMax™ Product in Canada Indicated to Temporarily Relieve Symptoms of Mental Fatigue and Sensation of Weakness and Support Cognitive Functions Including Mental Focus and Stamina

  3/4/2019

  RecalMax™ is the Twelfth Innovus Pharma Product Approved in Canada to Date

• Innovus Pharma Announces the Approval of its Diabasens® Product in Canada Indicated to Relieve Cutaneous Pain Associated with Diabetic Neuropathy

  3/1/2019

  Diabasens® is the Eleventh Innovus Pharma Product Approved in Canada to Date